EssilorLuxottica CEO says shares will recover lost ground

EssilorLuxottica shares have fallen more than 40% from their November record high, with CEO Francesco Milleri blaming tariffs, dollar weakness, geopolitical tensions, and rising smart-eyewear competition. He said the company’s medtech transformation should ultimately support a share-price recovery, while dismissing concerns that rivals have yet to launch meaningful competing products. The article is primarily a management outlook and sentiment update rather than a fresh financial catalyst.

Analysis

The market is treating this as a simple rerating story, but the more important issue is mix shift risk: the premium embedded in the wearables narrative only survives if the category expands faster than competitor announcements compress willingness to pay. If the consumer hardware layer gets crowded before the platform layer is monetized, multiple expansion can stall even if unit growth stays healthy, because investors were underwriting scarcity value rather than just earnings power.

A second-order risk is that the medtech pivot introduces a valuation transition period where capital intensity rises before the market can see clear revenue quality improvement. That creates a classic “good strategy, bad stock” window of several quarters, especially when macro headlines keep pressuring discretionary hardware and cross-border supply chains at the same time. In that setup, any delay in proving recurring, higher-margin medtech economics could extend the derating into the next reporting cycle.

The contrarian read is that the move may be oversold if the company’s product cadence remains ahead of true competition and the core franchise continues to fund the transition. The market is likely extrapolating announcement risk into realized share loss too early; for a category leader, the key variable is not whether rivals talk, but whether they can match distribution, design, and software integration within 12-18 months. If they cannot, today’s weakness becomes an opportunity to buy a temporary sentiment washout rather than a broken thesis.

Key Decisions for Investors

• Initiate a tactical long in META into the next 1-2 earnings cycles via call spreads rather than stock, targeting a rebound if the market re-prices competitive risk as only moderate; use downside-limited structure because the stock can remain range-bound while sentiment heals.
• If we own META shares, trim 20-30% strength and re-enter on a 10-15% pullback; the name is still vulnerable to multiple compression until there is proof that smart eyewear and medtech are accretive, not dilutive, to returns.
• Consider a pair trade: long META / short a high-beta consumer hardware or AR-exposed peer basket over 3-6 months; the goal is to isolate platform execution and distribution advantage while hedging category-wide disappointment.
• Do not chase the rally in any announced smart-eyewear competitors until there is shipped volume and software usage data; announcements alone are unlikely to justify sustained revenue pressure on META within the next quarter.
• Set a catalyst watch for the next product cycle and management commentary on medtech margins; if gross margin or operating expense discipline deteriorates, exit the long thesis quickly because the rerating can become self-reinforcing on the downside.